Precirix to present clinical study results of its HER2-targeting CAM-H2 compound at the 2024 SNMMI annual meeting

Brussels, Belgium, 10 June 2024 – Precirix NV, a clinical-stage biotechnology company developing precision radiopharmaceuticals in oncology, announces that the Company will present results from a safety and dosimetry study evaluating the HER2-directed radioligand CAM-H2 at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2024 annual meeting, 8-11 June in Toronto, ON.

Read full press release here +

Your browser is not supported. Update your browser for more security, speed and to make the most of this site.